君赛生物递表港交所 中信证券为独家保荐人

Company Overview - Junshi Biosciences has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - The company focuses on innovative cell therapies and drug development for solid tumors, aiming to create safer, more effective, accessible, and affordable immunotherapy solutions [1] Core Product - The core product, GC101, is the world's first tumor-infiltrating lymphocyte (TIL) therapy that does not require high-intensity lymphodepleting chemotherapy or IL-2 administration, potentially becoming the first TIL therapy approved for market in China [1] - Clinical data indicates that TIL therapy can provide curative effects for some late-stage cancer patients, showing long-term benefits for patients with advanced melanoma, non-small cell lung cancer, and breast cancer [1] Clinical Trials - Phase I clinical trials for TIL therapy have demonstrated objective response rates in various advanced metastatic solid tumors, including melanoma, non-small cell lung cancer, and cervical cancer [1] Therapy Characteristics - TIL therapy is a personalized treatment with breakthrough efficacy; however, its complex preparation process and clinical protocols lead to high costs and limited accessibility, restricting widespread application [1] - The company aims to innovate from production to clinical application to enhance the safety, accessibility, and affordability of TIL therapy while maintaining its curative potential [1] Industry Growth - The global oncology drug market is projected to grow to $253.3 billion by 2024, with a compound annual growth rate (CAGR) of 13.9% from 2020 to 2024 [2] - By 2030, the market is expected to expand to $452.5 billion, with a CAGR of 10.2% from 2024 to 2030, and reach $702.7 billion by 2035, with a CAGR of 9.2% from 2030 to 2035 [2] - In China, the oncology drug market is anticipated to reach RMB 258.2 billion in 2024, with a CAGR of 6.9% from 2020 to 2024, and is expected to accelerate to RMB 527.3 billion by 2030 [2]